Ravulizumab长期治疗成人非典型溶血性尿毒症综合征的疗效与安全性
该分析基于前瞻性临床试验NCT02949128的延伸期,评估Ravulizumab在成人aHUS患者中的长期疗效与安全性。中位随访76.7周,49例进入延伸期,4例新增完全TMA缓解,血小板、LDH、血红蛋白正常化及eGFR改善持续,未发生脑膜炎球菌感染或死亡。
要点
- Ravulizumab每8周给药可长期维持aHUS患者的TMA缓解。
- 延伸期未发生脑膜炎球菌感染或死亡,安全性可接受。
- 疗效持续与补体C5持续抑制相关。
核心结论
- Ravulizumab每8周给药对成人aHUS长期治疗有效且安全性可接受,治疗超过6个月可提供额外临床获益。
研究设计与样本
- 前瞻性临床试验NCT02949128的延伸期分析,共纳入58例成人aHUS患者,其中49例进入延伸期,中位随访76.7周(范围0.6-118.3周)。
主要发现
- 延伸期有4例额外患者达到完全TMA缓解。
- 血小板计数、血清LDH和血红蛋白的正常化在26周初始评估期后持续至末次随访。
- eGFR和患者生活质量的改善也持续至末次随访。
- 所有疗效终点均与补体C5的持续抑制相关。
- 大多数不良事件发生在初始评估期早期,延伸期显著减少;延伸期无患者发生脑膜炎球菌感染或死亡。
临床怎么用
- 对于成人aHUS患者,可考虑每8周给予Ravulizumab进行长期治疗,以维持TMA缓解并改善肾功能。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare, complex, multisystem disease of dysregulated complement activity, characterized by progressive thrombotic microangiopathy (TMA), acute kidney injury, and multiorgan dysfunction, which often progresses to chronic kidney disease. Results from the prospective clinical trial of ravulizumab (NCT02949128) reveal rapid resolution of TMA in patients with aHUS, with sustained efficacy and safety in a 26-week initial evaluation period. METHODS: The aim of this analysis was to characterize the long-term efficacy and the safety profile of ravulizumab in adults with aHUS who had completed the initial evaluation period of the trial. Complete TMA response, hematologic and kidney functions, and safety were evaluated for all patients available for follow-up in the extension period (median follow-up: 76.7 weeks; range: 0.6-118.3). This trial included a total of 58 patients, 49 of whom entered the extension period. RESULTS: A total of 4 additional patients achieved complete TMA response during the follow-up period. Normalization of platelet count, serum lactate dehydrogenase (LDH), and hemoglobin observed in the 26-week initial evaluation period was sustained until the last available follow-up, as were the improvements in the estimated glomerular filtration rate (eGFR) and patient quality of life. All efficacy endpoints were correlated with the sustained inhibition of complement C5. Most adverse events (AEs) occurred early during the initial evaluation period and decreased substantially during the extension period. No patient developed a meningococcal infection or died during the extension period. CONCLUSION: This analysis reveals that ravulizumab administered every 8 weeks is efficacious with an acceptable safety profile for the long-term treatment of adults with aHUS and provides additional clinical benefit beyond 6 months of treatment.
引用
- Barbour T, Scully M, Ariceta G, et al. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Rep. 2021. PMID: 34169200. doi:10.1016/j.ekir.2021.03.884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。